# Risk: __Lack of drug therapy options__ (PBN__Risk_1146)

## Property: has_RiskISO_Impact

* [Health and care](../RiskISO/PBN__RiskISO_Purpose_0)

## Property: has_RiskTechnology

* [antiviral drugs](../Technology/PBN__Technology_236)
* [anti-malaria drugs](../Technology/PBN__Technology_237)
* [anti-inflammatory drugs](../Technology/PBN__Technology_238)

## Property: has_RiskSubject

* [individuals infected with covid-19](../Stakeholder/PBN__Stakeholder_686)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskISO_Purpose

* [Safety and security](../RiskISO/PBN__RiskISO_Impact_0)

## Property: has_RiskOwner

* [pharmaceutical companies](../Stakeholder/PBN__Stakeholder_124)
* [medical researchers](../Stakeholder/PBN__Stakeholder_687)

## Property: has_RiskMitigation

* [Conduct clinical trials to determine the efficacy of drug therapies, develop new therapeutics](../RiskMitigation/PBN__RiskMitigation_1597)

## Property: has_RiskName

Delay in effective treatment and management of COVID-19 cases

## Property: has_RiskDescription

Limited evidence of the efficacy of drug therapies for treating COVID-19

## Property: has_RiskSource

* [barcelo_environmental_2020](../Article/PBN__Article_270)

## Property: has_RiskGBN

* [No](../RiskGBN/PBN__RiskGBN_0)

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

